abbreviatioNs AD = Alzheimer's disease; CERAD = Consortium to Establish a Registry for Alzheimer's Disease; CSF = cerebrospinal fluid; GDS = Global Deterioration Scale; HVLP = high-volume lumbar puncture; NPH = normal pressure hydrocephalus. obJective Normal pressure hydrocephalus (NPH) remains most often a clinical diagnosis and has been widely considered responsive to the placement of a cerebrospinal fluid (CSF) shunt. The high incidence of patients with Alzheimer's disease (AD) with NPH symptoms leads to poorer outcomes than would be expected in patients with NPH alone. This article reviews a series of patients operated on for presumed NPH in whom preoperative high-volume lumbar puncture (HVLP) and intraoperative cortical brain biopsies were performed. The data derived from these procedures were then used to understand the incidence of AD in patients presenting with NPH symptoms and to analyze the efficacy of HVLP in patients with NPH and patients with concurrent AD (NPH+AD). A review of the outcomes of shunt surgery is provided. methods The cases of all patients who underwent placement of a CSF shunt for NPH from 1998 to 2013 at the University of Virginia by the senior author were retrospectively reviewed. Patients who underwent HVLP and patients who underwent cortical brain biopsies were stratified based on the biopsy results into an NPH-only group and an NPH+AD group. The HVLP results and outcomes were then compared in these 2 groups. results From 1998 to 2013, 142 patients underwent shunt operations because of a preoperative clinical diagnosis of NPH. Of the patients with a shunt who had a diagnosis of NPH, 105 (74%) received HVLPs. Of 142 shunt-treated patients with NPH, 27 (19%) were determined to have concomitant Alzheimer's pathology based on histopathological findings at the time of shunting. Patients who underwent repeat biopsies had an initial positive outcome. After they clinically deteriorated, they underwent repeat biopsies during shunt interrogation, and 13% of the repeat biopsies demonstrated Alzheimer's pathology. Improvements in gait and cognition did not reach significance between the NPH and NPH+AD groups. In total, 105 patients underwent HVLP before shunt placement. In the NPH cohort, 44.6% of patients experienced improvement in symptoms with HVLP and went on to experience resolution or improvement. In the NPH+AD cohort, this proportion was lower (18.2%), and the majority of patients who experienced symptomatic relief with HVLP actually went on to experience either no change or worsening of symptoms (p = 0.0136). coNclusioNs A high prevalence of AD histopathological findings (19%) occurred in patients treated with shunts for NPH based on cortical brain biopsies performed during placement of CSF shunts. HVLP results alone were not predictive of clinical outcome. However, cortical brain biopsy results and the presence of Alzheimer's pathology had a strong correlation with success after CSF shunting. Thirteen percent of patients who initially had a normal cortical brain biopsy result had evidence of AD pathology on repeat biopsy, demonstrating the progressive nature of the disease.
1965, neurosurgical management with cerebrospinal fluid (CSF) shunting has been the recommended treatment. However, the identification of patients with NPH most likely to benefit from shunting procedures remains difficult. 8, 17, 21 Marmarou et al. performed a literature review and found that the sensitivity of predicting successful outcomes based on clinical and imaging findings alone can be as low as 46%. The addition of high-volume lumbar puncture (HVLP) yielded a sensitivity of 26%-61%, and CSF outflow resistance studies had sensitivities of 57%-100%. 10 Neurological comorbidities like Alzheimer's disease (AD) have been hypothesized to hinder shunt responsiveness in patients with NPH. 3 But it is difficult to differentiate patients with NPH from patients with AD by history and physical examination alone. In an effort to determine what percentage of patients with the clinical triad of NPH have AD, several studies have analyzed cortical brain biopsies obtained from subjects with NPH during placement of CSF shunts. The incidence of AD in these patient populations varied from 18%-75%. 2, 5, 7, 9, 16 Cabral and colleagues reviewed brain autopsy reports and found that 89% of a cohort of patients with NPH also had AD. 3 If patients with AD could be identified and excluded from the population of patients who present with the triad of NPH, then improved outcome measures would be expected.
In the present study, we retrospectively reviewed a cohort of patients who underwent shunt placement and had cortical brain biopsies performed by the senior author for presumed NPH over a 15-year period. The results of HVLPs, cortical brain biopsies, and clinical improvement following shunting is reviewed and compared between the patients with NPH and those with NPH plus Alzheimer's pathology found on cortical brain biopsies.
methods
Following institutional review board approval, all patients operated on by the senior author (J.A.J.) from 1998 to 2013 at the University of Virginia Health Science Center were identified from a departmental database. All patients who had undergone placement of a ventriculoperitoneal shunt for a preoperative diagnosis of NPH were included in the study. Patients were selected for shunting based on clinical history, physical examination, radiological findings, and neuropsychological and physical therapy review before and after an HVLP was performed. All patients were evaluated and followed up in a clinical setting by the senior author who performed the shunt procedure, or another clinician at the same institution. Average follow-up time was 34.7 months. Patient demographics, presenting symptoms, preoperative and postoperative radiographic imaging and reports, physical therapy assessments before and after lumbar puncture, neuropsychological assessments before and after lumbar puncture, operative notes, histology reports, and follow-up clinic reports were reviewed.
Clinical outcomes were categorized as full resolution of symptoms, improvement, no change, worsened, or unknown based on patient and family reports. Within the limitations of the pathological diagnosis of AD performed in a single frontal biopsy, the diagnosis of "neuropathologic findings consistent with AD" was established when a clinical history of dementia was present coupled with the relative density of neuritic plaques, as established by criteria outlined by the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) classification scheme in a joint publication by the National Institute on Aging and the Reagan Institute. 11, 12 Annotation of the presence of neurofibrillary disease and amyloid angiopathy was also performed.
Statistical significance calculations were obtained using ANOVA and the chi-square test. Categorical variables were compared using Fisher's exact test. For all statistical tests, a p value < 0.05 was considered significant.
From 1998 to 2013, 142 patients underwent shunt operations for a preoperative diagnosis of NPH. Of the shunttreated patients who had a diagnosis of NPH, 105 (74%) received HVLPs and pre-and postprocedural inpatient evaluations conducted by a combination of a neuropsychologist, occupational therapist, or a physical therapist. At the time of surgery, 159 total cortical brain biopsies were performed; 46 were repeat biopsies from the original 113 (80%) unique patients who underwent biopsies during primary shunt implantation. Biopsies were only obtained when patients and their families consented to the biopsy to obtain further information on the presence of comorbid neurodegenerative disease.
preoperative assessment
Routine histories and physical examinations were performed at the initial clinic visit and/or hospital admission. Patients also underwent high-resolution MRI, using standard T1-and T2-weighted spin echo sequences, or CT scanning. Imaging studies were independently reviewed at diagnosis by a neuroradiologist and the senior author.
A preoperative diagnosis of NPH was determined through a combination of dyspraxic gait instability, impaired cognition, urge urinary incontinence, and MRI or CT findings consistent with ventriculomegaly out of proportion to cerebral atrophy. The diagnosis of NPH and hence the decision to proceed with a shunting procedure were independent of the possible diagnosis of other concomitant conditions or the cerebral biopsy findings, which were only known after the placement of a ventriculoperitoneal shunt.
Over the time period reviewed, 113 patients underwent a baseline assessment of neuropsychological function that included neurocognitive functioning across multiple domains, including memory, language, attention and mental status, control, and formal gait/balance and motor skills. Of these patients, 105 also received HVLP with pre-and postprocedural assessment of functioning to measure changes in cognitive and psychomotor abilities. In addition to a clinical interview, the following tests were administered: Mini-Mental State Exam (MMSE); Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); Wechsler Memory Scale, Third Edition (WMS-III); Grooved Pegboard Test; and Graphomotor Sequences. These measures were repeated following HVLP procedures. Gait assessment included the time and number of steps necessary to walk 10 m as well as the time to make two 360° rotations. Improvement in gait was determined as a decrease in the amount of time and num-ber of steps needed. These evaluations were performed by a neuropsychologist and, in most instances, an occupational and/or physical therapist also and were reviewed by the senior author. Lumbar punctures were performed in the hospital setting in the usual sterile fashion at the L3/4 or L4/5 interspace with an average of 34.1 ml of CSF removed. CSF pressure was measured before and after fluid was removed with the patient in a recumbent position.
operative procedure and sample preparation
The operative procedure for placement of a ventriculoperitoneal shunt is well known.
1,13,24 Unless contraindicated, patients underwent placement of a right frontal ventriculoperitoneal shunt with placement of the peritoneal catheter through a subxyphoid midline incision. The Codman-Hakim programmable valve system was used in most procedures with an initial setting of 100-120 mm H 2 O. In more recent patients, the authors have moved to a Medtronic Strata programmable valve with an initial setting of 1.0 and Sophysa Polaris SPV-200 programmable valves with an initial setting of 110 mm H 2 O. Patients were not stratified in the analysis based on valve system. Clinical improvements and adverse effects to these programmable settings were observed, recorded, and reviewed; pressure adjustments continued to be performed until optimal settings were attained for each patient.
The cortical brain biopsy was performed after the dura was opened following bur hole creation. A region of cortex was identified free of overlying vessels and a sample of cortex approximately 3 × 3 × 5 mm was obtained and fixed in neutral buffered formalin.
All specimens, after fixation, were processed into paraffin blocks and shaved for histological examination. Consecutive sections were further examined with H & E stain as well as modified silver Bielschowsky stain and immunohistochemical stains for b-amyloid and hyperphorylated tau protein. In a few cases, immunohistochemical staining for a-synuclein was also performed. A neuropathologist, blinded to the presence of any clinical comorbidities or shunt outcome, reviewed these biopsy specimens for the presence of pathological changes in the cerebral parenchyma, such as inflammation, neoplastic process, neuritic and diffuse plaques, amyloid angiopathy, neurofibrillary tangles, Lewy bodies, and other intracellular inclusions.
Patients who exhibited clinical deterioration following initial shunting, and who consented to both shunt interrogation and biopsy, were candidates for repeat biopsy.
results patient demographics and presenting symptoms
Patient demographics are summarized in Table 1 . Mean age was 75.6 years at presentation (range 43.7-88.4 years). Of these patients, 27 (19%) were determined to have concomitant Alzheimer's dementia based on histopathological findings at the time of shunting. There was no significant difference in distribution of age or sex. At presentation, most patients (68%) were between 70-90 years of age; 2 were between 40-50, 3 were between 50-60, 30 were between 60-70, 66 were between 70-80, and 31 were between 80-90.
All 142 patients presented with one or a constellation of symptoms consistent with idiopathic NPH, including cognitive disturbance, gait difficulties, and urinary incontinence (Table 2 ). Approximately 82% of the total patients exhibited the full triad of symptoms, 92% exhibited some form of memory disturbance (by subjective report and confirmed by testing), 87% presented with urinary disturbance, and 98% experienced gait difficulty. There was no significant difference in these symptoms between groups (p = 0.6903, 0.7492, and 0.4715, respectively). Interestingly, 10/115 (9%) patients in the NPH group and 1/27 (4%) patient in the NPH+AD group presented without any memory disturbance, though this was not a significant difference (p = 0.6903). Gait imbalance, either alone or in combination with other symptoms, was the most common presenting feature at presentation.
high-volume lumbar puncture
A total of 105 patients (83 with NPH, 22 with NPH+AD) underwent HVLP before shunt placement. Overall, 80 of 105 patients experienced some form of relief in symptoms (59%)experienced improvement in gait and 37% experienced improvement in cognition). More patients experienced improvement in gait and/or cognition in the NPH group than in the NPH+AD group, though this was not statistically significant (64% improved gait in the NPH versus 41% in the NPH+AD group, p = 0.2326 and 40% improved cognition in the NPH versus 27% in the NPH+AD group, p = 0.3292). A higher proportion of patients with NPH+AD experienced any kind of improvement following HVLP (77% vs 76% in the NPH group), though this difference was not statistically significant (p = 1.0000). These results are illustrated in Table 3 .
There appeared to be a statistically significant correlation between immediate response to HVLP and progression of symptoms over the course of follow-up. In the NPH cohort, 45% of patients experienced improvement in symptoms with HVLP and went on to experience resolution or improvement of symptoms versus 18% in the NPH+AD cohort. The majority of NPH+AD patients who experienced symptomatic relief with HVLP actually went on to experience either no change or worsening of symptoms (p = 0.0136).
Neuropathology
A total of 159 cortical brain biopsies were performed during shunt procedures in 113 individual patients, with 46 repeat biopsies across 36 individual patients. The aggregate number of biopsies that revealed neuritic plaques was 78 (49%), neurofibrillary tangles was 19 (12%), and amyloid angiopathy was 15 (9%). With regards to individual biopsies, 53% of patients exhibited neuritic plaques, 14% had neurofibrillary tangles, and 9% had amyloid angiopathy.
Of the 113 patients who received cortical brain biopsies, 27 patients were diagnosed with AD based on pathognomonic neuropathologic changes along with clinical symptoms, suggesting a co-occurrence of 24% with NPH. Only one of these biopsies did not reveal neuritic plaques, but rather extensive neurofibrillary disease. Alternatively, 60 patient biopsies revealed the presence of any number of neuritic plaques, which might suggest a much higher rate (53%). Of the 36 patients who had repeat biopsies, 5 had histopathologic evidence suggestive of an AD diagnosis. One of the 5 patients (20%) diagnosed with AD on repeat biopsy did not have histopathologic changes consistent with AD on the original brain biopsy. The breakdown of these findings is shown in Table 4 .
Compared with patients in the NPH-only cohort, patients with a diagnosis of concurrent AD on initial biopsy exhibited a much higher proportion of neuritic plaques (96%, p < 0.0001), neurofibrillary tangles (41%, p < 0.0001), and cerebral amyloid angiopathy (30%, p = 0.0001). These patients' biopsies also stained positive on histochemical and immunohistochemical stains much more frequently: 70% were positive for Bielschowsky stain (p = 0.0017), 93% for β-4-amyloid (p < 0.0001), and 52% for tau (p < 0.0001). Based on these criteria, 34 of 113 biopsies suggested CERAD Grade A, 19 suggested Grade B, and 7 suggested Grade C.
outcomes
Clinical symptom outcomes are summarized in Table  5 . Over a mean clinical follow-up of 34.7 months, 70 patients (49%) experienced either improvement or complete resolution of symptoms. All of the 6 patients who experienced complete resolution were diagnosed with only NPH, and their ages ranged from 65.4 to 86.5 years (no patients with concomitant AD exhibited such a drastic improvement in symptoms). Of the 115 patients with NPH only, 62 (54%) experienced improvement or complete resolution of symptoms, which was significantly different from 8 (30%) of the 27 patients with NPH+AD (p = 0.0317). In the NPH-only group, 16 (14%) patients had a progression of presenting symptoms, whereas 6 (22%) patients in the AD group had worsening of symptoms, though this difference was not statistically significant (p = 0.3732). Of note, 17 (15%) patients with NPH and 2 (7%) with AD died over the course of follow-up.
Patients with a histopathological diagnosis of concurrent AD can be further subclassified by relative density of neuritic plaques into CERAD Grades A, B, or C 11, 12 as follows: CERAD Grade A (sparse, low probability of AD), CERAD Grade B (intermediate, medium probability of AD), or CERAD Grade C (frequent, high probability of AD). Of the 26 patients in the NPH+AD cohort with identifiable neuritic plaques on cortical biopsy (1 patient biopsy did not show plaques but rather extensive neurofibrillary tangles and tau deposition), 10 were found to have sparse plaques (CERAD Grade A), 12 intermedi- ate plaques (CERAD Grade B), and 4 frequent plaques (CERAD C), conferring a low, medium, and high probability of AD, respectively. No patients with concurrent AD had complete resolution of symptoms. However, 50% of patients with NPH+AD CERAD Grade A classification had symptomatic improvement and 25% of patients classified as CERAD Grade B had improvement, but none of the CERAD Grade C-classified patients had any improvement over the course of follow-up, though these differences were not statistically significant (CERAD Grade A vs B, p = 0.3777; Grade A vs C, p = 0.2208; Grade B vs C, p = 0.5286). Table 5 displays the relevant information of symptoms observed in follow-up by CERAD category. In all, 46 repeat biopsies were performed in 36 unique patients (28 patients had 1 repeat biopsy, 6 had 2 repeat biopsies, and 2 had 3 repeat biopsies). Of all of these repeat biopsies, 6 biopsies (13%) suggested histopathological changes consistent with AD. These changes were observed across 5 unique patients (1 patient had 2 repeat biopsies that revealed AD both times). Of the 36 unique patients with repeat biopsies, 32 (89%) did not have evidence of AD on the initial biopsy and 4 (11%) did have evidence of AD on the initial biopsy. One patient who did not have evidence of AD on the initial biopsy had AD on the repeat biopsy (1/32 = 3%). Of the 5 patients with AD on the repeat biopsy, 4 (80%) had initial improvement in symptoms following the initial ventriculoperitoneal shunting procedure and 1 (20%) did not experience any improvement following surgery. All of the 4 patients with initial improvement eventually experienced recurrence and worsening of symptoms. Notably, one of these patients presented with gait instability as the predominant symptom and went on to experience worsening urinary incontinence.
discussion
In this study of a cohort of 142 patients who underwent CSF shunting procedures for presumed NPH over a 15-year period, 19% of all patients (and 24% of biopsied patients) exhibited neuropathologic changes consistent with the CERAD criteria for AD.
11 This finding appears to be consistent with the co-occurrence of NPH-AD reported in the literature of approximately 18%-42%, including 75% of those with severe dementia. 2, 5, 7, 9, 16 The prevalence of AD pathology in patients with NPH reportedly increases in proportion to the severity of dementia. 7 More recently, Cabral and colleagues reported 89% of clinically diagnosed NPH patients (n = 9) were found to have AD at autopsy. 3 The prevalence of AD pathology in NPH and its variability reported in the literature may be partly attributable to NPH clinical diagnostic criteria. Cabral's result suggests that, in the patients who will ultimately develop AD, NPH is an early clinical indicator. Our results suggest that early shunting in patients with progressive AD may improve patient's symptoms. Furthermore, shunting in patients with later stage AD, as evidenced by CERAD Grades B and C pathologic criteria, does not appear to be beneficial.
The clinical characteristics at baseline were largely consistent with the constellation of gait, cognitive, and urinary disturbances, and no significant differences were observed in the clinical presentation of patients with NPH or NPH+AD. The prevalence of AD pathology has been shown to correlate with cognitive impairment, as measured by the Global Deterioration Scale (GDS) with 18% of patients with a GDS score of 3 and 75% of patients with a GDS score 6 and above found to have concurrent AD. 7 Detailed histopathological assessment at the time of surgery revealed the importance of the presence and density of neuritic plaques in unearthing concomitant neurodegenerative disease. Neuritic plaques were observed in nearly half of all patient biopsies (49%), and patients with presumed AD exhibited a statistically significantly higher proportion of plaques, neurofibrillary tangles, and cerebral amyloid angiopathy (p < 0.0001, p < 0.0001, and p = 0.0001, respectively). Looking at these findings with higher granularity suggests that the majority of patients diagnosed with concurrent AD exhibited sparse to intermediate plaque density (37% CERAD Grade A and 44% CERAD Grade B).
One of the more salient findings of the current study was the statistically significant difference in shunt responsiveness between groups (54% of NPH patients vs 30% of NPH+AD, p = 0.0317, Table 5 ). These patients showed either complete resolution of symptoms (all of these patients were in the NPH-only cohort) or improvement in symptoms to the point of improving activities of daily life. The density of plaques (CERAD Grades A, B, and C) seemed to be inversely proportional to responsiveness to shunting as measured by resolution or improvement in symptoms, though these differences were not statistically significant. Patients with NPH and concurrent AD would be expected to experience progressively worsening symptoms, 7,20 but shunting procedures may in fact attenuate long-term disease burden and dampen an otherwise accelerated and aggressive trajectory of decline in neurological function. The data indicate that if patients were to undergo cortical brain biopsies before committing to CSF shunting, then the patients in the CERAD Grade B and C subgroups would avoid having received unnecessary CSF shunts (12% of all NPH CSF shunt placements), while only missing the small subgroup of CERAD B patients, which had a positive outcome (3 patients).
There is disagreement with regard to the validity of a true NPH diagnosis and the long-term benefits of shunting versus the risks and complications of surgery. 22 Recent literature has demonstrated the consistently greater success in treating the gait disturbance and incontinence of NPH with minimal improvement in cognition. 3 One theory advanced by Silverberg points to the prospect of fixed tissue damage and a dementing process with multifactorial origins. 18 While an exact pathophysiological link between AD and NPH is not known, one explanation might rest on altered CSF dynamics resulting in pathologic accumulation of β-amyloid in the brain. 6, 20 Investigators have also noted that NPH as a single entity may be quite rare and that an AD-NPH syndrome may manifest as a result of coexisting NPH and AD pathology. 4, 15, 20 Idiopathic NPH seems to involve an underlying pathophysiology wide in scope, one that ranges from hemodynamic disturbance to major cerebral parenchymal changes. NPH may share pathogenic pathways associated with AD, specifically CSF stasis that might result in reduced clearance of neurotoxic macromolecules. 2 Studies have revealed poor outcomes in terms of cognitive improvement after shunt placement in individuals with NPH and concomitant AD, perhaps challenging the idea that simply restoring proper CSF circulation does not wholly reign as a therapeutic option. 19 However, our data would indicate that if NPH is an early clinical indicator of AD, then the timing of when the CSF shunts are placed determines the overall outcome.
The use of HVLP, or lumbar drain trials, to assess the usefulness of shunting in patients with NPH symptoms is not novel. These data demonstrated that > 75% of the patients in both the NPH and NPH+AD groups had improvement in symptoms after HVLP. This did not directly correlate with clinical outcomes following shunt placement in this series. There was a significant difference in improvement after shunting between NPH-only patients with improved HVLP results versus the NPH+AD patients (45% vs. 18%, p = 0.0136). Unfortunately, the diagnosis of AD is a clinical and histological diagnosis that cannot be confirmed until a brain biopsy is performed. These data provide some insight into why some patients have failed outcomes despite positive HVLP results, but these data do not improve our ability to screen patients on initial presentation. We have found that having the brain biopsy results in further clinic assessments is a valuable tool for discussions with families regarding future shunt interrogations when patients experience further cognitive decline. The data would support obtaining a cortical brain biopsy prior to committing the patient to shunting to improve the likelihood of obtaining improvement in symptoms.
The present study has several strengths, chief among them being the number of patients and the longitudinal nature of follow-up relative to other retrospective reports in the literature. Comprehensive neuropathological, radiographic, and neuropsychological examinations were instrumental in confirming prospective diagnoses of concurrent NPH and AD. Going forward, longitudinal follow-up studies with special emphasis on the presence of concomitant neurological conditions in patients with NPH will help to further elucidate the potential mechanisms of cerebral pathological change underlying these disorders. With a richer grasp of the etiological underpinnings of these clinical entities, we may further be able to refine diagnostic criteria, predict symptomatic progression, and accordingly match appropriate surgical and nonsurgical therapeutic modalities to patient functioning.
conclusions
A high prevalence of AD neuropathological findings was found in patients receiving shunts for NPH (24%), which was reflected by neurodegenerative changes consistent with AD on neuropathological biopsies. A significant correlation was found between the presence of AD comorbidity and shunt outcome, though the density of neuropathological features had no significant impact on symptoms over the follow-up period. All of the patients who exhibited histopathological changes consistent with AD on repeat biopsy had a clinical course ultimately characterized by recurrence and worsening of presenting symptoms, though the majority of these patients enjoyed initial clinical improvement following ventriculoperitoneal shunting. Obtaining a cortical brain biopsy either during primary placement of a shunt, or prior to committing to a shunt, provides valuable information and correlates with clinical outcomes following shunt surgery.
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